Welcome to our dedicated page for Acumen Pharmaceuticals news (Ticker: ABOS), a resource for investors and traders seeking the latest updates and insights on Acumen Pharmaceuticals stock.
Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), headquartered in Charlottesville, VA with additional offices in Indianapolis, IN and Newton, MA, is a clinical-stage biopharmaceutical company innovating in the field of Alzheimer's disease (AD) and other neurodegenerative disorders. Acumen's core focus is on the development of novel, disease-modifying treatments by targeting toxic soluble amyloid-beta oligomers (AβOs), which are believed to be a primary underlying cause of AD. The company’s lead therapeutic candidate, sabirnetug (ACU193), is a humanized monoclonal antibody designed to selectively target these AβOs, thereby preventing synaptic dysfunction and neurodegeneration.
Acumen's scientific founders are pioneers in AβO research, contributing to decades of understanding in the field. This extensive research has culminated in the development of sabirnetug, which demonstrated positive topline results from the Phase 1 INTERCEPT-AD clinical trial. The trial showed that sabirnetug is well-tolerated, with a favorable safety profile, and demonstrated statistically significant, dose-related amyloid plaque reduction, validating its proof-of-mechanism.
Currently, Acumen is advancing sabirnetug into the Phase 2 ALTITUDE-AD trial, which aims to further evaluate its clinical efficacy and safety in early Alzheimer's disease. The company is also planning a Phase 1 study to explore a subcutaneous dosing option, enhancing patient accessibility and treatment convenience.
Acumen Pharmaceuticals remains committed to advancing its pioneering research into practical therapeutic solutions. The company's strategic partnerships, including a recent collaboration with Lonza for the manufacturing of sabirnetug, underscore its dedication to bringing effective treatments to market. With a strong financial footing, including $296.6 million in cash and marketable securities as of March 31, 2024, Acumen is well-positioned to support its clinical and operational activities into the first half of 2027.
Acumen’s mission is driven by the urgent need for safe and effective treatment options for Alzheimer's patients. Their work continues to be fueled by robust scientific insights and a commitment to improving the lives of those afflicted by AD.
Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) will participate in a fireside chat at the Stifel Healthcare Conference on November 16, 2022, at 4:10 p.m. ET. The live webcast will be accessible under the Investors tab on Acumen's website, where it will be archived for 14 days.
Acumen focuses on developing novel therapeutics for Alzheimer’s disease, targeting toxic soluble AβOs with its investigational product candidate, ACU193, currently in a Phase 1 clinical trial for early Alzheimer’s patients.
Acumen Pharmaceuticals (NASDAQ: ABOS) will announce its Q3 2022 financial results on November 14, 2022, followed by a conference call at 4:30 p.m. ET. This call aims to provide a comprehensive business and financial update regarding the company's operations. Acumen is focused on developing innovative therapeutics for Alzheimer's disease, specifically targeting soluble AβOs with its candidate ACU193 in a Phase 1 clinical trial.
Acumen Pharmaceuticals announced the publication of its clinical development plan for ACU193, a monoclonal antibody targeting toxic soluble amyloid beta oligomers, in the Journal of Prevention of Alzheimer’s Disease. The ongoing Phase 1 clinical trial, INTERCEPT-AD, aims to evaluate the safety and efficacy of ACU193 in early Alzheimer’s disease patients. The FDA has granted Fast Track designation for this therapy, which may accelerate its path to market. Future trial phases will be guided by safety, pharmacokinetics, and cognitive measures for potential registration.
Acumen Pharmaceuticals (NASDAQ: ABOS) announced that its investigational drug, ACU193, has received Fast Track designation from the FDA for treating early Alzheimer’s disease. ACU193 targets toxic soluble amyloid beta oligomers, which are believed to contribute to neurodegeneration. Currently in the Phase 1 INTERCEPT-AD trial, the drug aims to establish safety and proof of mechanism with 62 participants. The Fast Track status facilitates closer collaboration with the FDA, enhancing the potential for expedited review and approval.
Acumen Pharmaceuticals (NASDAQ: ABOS) reported financial results for Q2 2022, revealing a cash balance of $209.9 million as of June 30, anticipated to fund operations until 2025. The ongoing INTERCEPT-AD Phase 1 trial for ACU193 aims to deliver topline results in H1 2023, with 15 active clinical sites currently enrolling patients. R&D expenses surged to $7.3 million, reflecting increased clinical trial costs. Net loss decreased to $10.2 million compared to $61.4 million a year prior, influenced by significant prior year non-cash expenses.
Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) will announce its Q2 2022 financial results on August 15, 2022, followed by a conference call at 4:30 p.m. ET. The company focuses on novel therapies for Alzheimer’s disease and is advancing its investigational drug, ACU193, in a Phase I clinical trial. Acumen has established itself in the biopharmaceutical sector, targeting the toxic Aβ oligomers linked to Alzheimer’s pathology. The audio from the call will be accessible via their website, with an archived version available for 30 days.
Acumen Pharmaceuticals has developed a synthetic model for soluble amyloid beta oligomers (AβOs), crucial for Alzheimer’s disease research. This model aims to standardize assays for AβOs, which have been challenging to study due to their complexity. The methodology will be presented at the Alzheimer’s Association International Conference (AAIC) from July 31 to August 4, 2022. The ongoing Phase 1 clinical trial of ACU193, targeting toxic AβOs, is expected to yield important data to advance Alzheimer’s research.
Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) announced its participation in two upcoming major conferences focusing on Alzheimer's disease. At the Alzheimer’s Association International Conference (AAIC) in San Diego, the company will present a poster on August 3, 2022, detailing their research on amyloid beta oligomers. Additionally, Dr. Eric Siemers, Chief Medical Officer, will speak at the BTIG Biotech Conference on August 8, 2022, discussing next-generation therapeutics targeting Alzheimer's pathology. Acumen is advancing its investigational product ACU193, a monoclonal antibody in Phase 1 trials.
Acumen Pharmaceuticals (NASDAQ: ABOS) reported its Q1 2022 financial results, highlighting a cash balance of $216.7 million as of March 31, 2022, sufficient to fund operations through 2025. The company is advancing its Phase 1 clinical trial, INTERCEPT-AD, for its drug ACU193 targeting early Alzheimer’s disease, with topline data expected in the first half of 2023. R&D expenses increased to $6.0 million from $2.6 million YoY, reflecting ongoing trial costs. Acumen's net loss for the quarter was $9.1 million, a decrease from $27.0 million in Q1 2021.
Acumen Pharmaceuticals (NASDAQ: ABOS) will announce its Q1 2022 financial results on May 16, 2022, at 4:30 PM ET. The company will host a conference call and a live audio webcast to discuss business performance and financial updates. Acumen is focused on developing a novel therapy for Alzheimer’s disease, specifically targeting toxic AβOs through its investigational drug, ACU193, currently in Phase I trials. Interested investors can access the live webcast via the company’s website.
FAQ
What is the current stock price of Acumen Pharmaceuticals (ABOS)?
What is the market cap of Acumen Pharmaceuticals (ABOS)?
What is Acumen Pharmaceuticals’ main focus?
What is sabirnetug (ACU193)?
What were the results of the Phase 1 INTERCEPT-AD trial?
What is the Phase 2 ALTITUDE-AD trial?
What are some recent achievements of Acumen Pharmaceuticals?
What is Acumen’s financial condition?
Where is Acumen Pharmaceuticals headquartered?
What is the significance of targeting amyloid-beta oligomers (AβOs)?
What future plans does Acumen Pharmaceuticals have for sabirnetug?
How can investors get more information about Acumen Pharmaceuticals?
